Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein S34 (MRPS34) is a nuclear-encoded protein and a structural constituent of the mitochondrial small (28S) ribosomal subunit. It is essential for mitochondrial protein synthesis by facilitating the stability of the small ribosomal subunit and the 12S rRNA, both required for efficient mitoribosome formation and maintenance. Mutations in MRPS34 disrupt mitochondrial translation, compromise the stability of the 12S rRNA, reduce mitochondrial respiratory complex activity, and result in mitochondrial dysfunction and inherited disorders such as combined oxidative phosphorylation deficiency 32 and Leigh syndrome. MRPS34 does not act as a classical drug target (e.g., enzyme or receptor) but is instead classified as a ribosomal structural protein involved in mitochondrial gene expression and energy production, and disruptions to its function have direct clinical relevance in mitochondrial pathologies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein S34 (MRPS34).